XenoPort Director John Gordon Freund Purchases 12,500 Shares (XNPT)
XenoPort (NASDAQ:XNPT) Director John Gordon Freund purchased 12,500 shares of the company’s stock on the open market in a transaction dated Tuesday, June 3rd. The stock was purchased at an average cost of $3.93 per share, with a total value of $49,125.00. Following the acquisition, the director now directly owns 8,899 shares of the company’s stock, valued at approximately $34,973. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
XenoPort (NASDAQ:XNPT) opened at 4.14 on Friday. XenoPort has a one year low of $3.15 and a one year high of $7.20. The stock has a 50-day moving average of $3.91 and a 200-day moving average of $5.21. The company’s market cap is $256.2 million.
XenoPort (NASDAQ:XNPT) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.32) by $0.04. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.86 million. During the same quarter in the prior year, the company posted ($0.50) earnings per share. The company’s quarterly revenue was up 639.1% on a year-over-year basis. On average, analysts predict that XenoPort will post $-1.46 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of XenoPort in a research note on Thursday, May 15th. They now have a $6.00 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of XenoPort from $12.00 to $10.00 in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $6.22.
XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.